Abstract
Treatment recommendations for mastocytosis are based mostly on expert opinion rather than evidence obtained from controlled clinical trials. In this article, treatment options for mastocytosis are presented, with a focus on the control of mediator-related symptoms in patients with indolent disease.
Keywords:
Anti-IgE; Antihistamine; Antimediator therapy; Mastocytosis; Mediator-related symptoms; Platelet-activating factor.
Copyright © 2014 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
1-Alkyl-2-acetylglycerophosphocholine Esterase / genetics
-
1-Alkyl-2-acetylglycerophosphocholine Esterase / immunology
-
Antibodies, Anti-Idiotypic / therapeutic use*
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Bone and Bones / drug effects
-
Bone and Bones / immunology
-
Bone and Bones / pathology
-
Central Nervous System / drug effects
-
Central Nervous System / immunology
-
Central Nervous System / pathology
-
Dasatinib
-
Gastrointestinal Tract / drug effects
-
Gastrointestinal Tract / immunology
-
Gastrointestinal Tract / pathology
-
Gene Expression
-
Histamine Antagonists / therapeutic use*
-
Humans
-
Mast Cells / drug effects*
-
Mast Cells / immunology
-
Mast Cells / pathology
-
Mastocytosis / drug therapy*
-
Mastocytosis / genetics
-
Mastocytosis / immunology
-
Mastocytosis / pathology
-
Omalizumab
-
Protein Kinase Inhibitors / therapeutic use*
-
Proto-Oncogene Proteins c-kit / antagonists & inhibitors
-
Proto-Oncogene Proteins c-kit / genetics
-
Proto-Oncogene Proteins c-kit / immunology
-
Pyrimidines / therapeutic use
-
Skin / drug effects
-
Skin / immunology
-
Skin / pathology
-
Thiazoles / therapeutic use
Substances
-
Antibodies, Anti-Idiotypic
-
Antibodies, Monoclonal, Humanized
-
Histamine Antagonists
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Thiazoles
-
anti-IgE antibodies
-
Omalizumab
-
Proto-Oncogene Proteins c-kit
-
1-Alkyl-2-acetylglycerophosphocholine Esterase
-
PLA2G7 protein, human
-
nilotinib
-
Dasatinib